Octagon Capital Advisors

Congratulations to our portfolio company Cullgen Inc. on their merger with Pulmatrix Inc.! Additional details can be found in the post below: https://lnkd.in/dgHbK2Qz We are excited for the company's listing on Nasdaq and look forward to continue being shareholders as they develop their degrader pipeline. Congratulations again to the entire Cullgen Inc. team! *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

Congratulations to the Aktis Oncology team on their $175M oversubscribed Series B financing! Additional details can be found in the post below: https://lnkd.in/eZ5shSqx In addition to the Series B investment, Octagon had previously invested in Aktis' Series A and Series A+ financings.?We look forward to continuing our partnership with Matthew Roden and the rest of the Aktis Oncology team as they continue to further advance their radiopharmaceuticals pipeline. *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

Congratulations to our portfolio company Numab Therapeutics AG on their announcement that Johnson & Johnson has entered into a definitive agreement to acquire its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion.??Additional details can be found in the press release below: https://lnkd.in/erfpth76 This transaction validates Numab's platform and we are excited to continue partnering with them. Great job by the entire Numab Therapeutics AG team! *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

Congratulations to our portfolio company Aktis Oncology on their collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals. Additional details can be found in the press release below: https://lnkd.in/eupbNY4q We are super excited for the Aktis team! *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

Congratulations to our portfolio company Bluejay Therapeutics on successfully raising a $182m oversubscribed Series C financing round! Additional details can be found in the press release below:? ? https://lnkd.in/duthsvzW In addition to the Series C investment, Octagon had previously invested in Bluejay’s Series A and Series B financings.?We are inspired by Bluejay’s progress to date and look forward to continuing to be a thought partner for Keting Chu and the management team as they continue to grow their platform. *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

We are thrilled to share that Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced that it has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals (Nasdaq: VRTX) for $65.00 per share in cash, or a total of $4.9 billion. Below is a link to the press release: ? https://lnkd.in/evPRBg7J ? Octagon began investing in Alpine in September 2022 and grew the position to be one of our largest core holdings.?We are elated that Vertex recognizes Alpine’s talented team along with their protein engineering and immunotherapy capabilities.?Congratulations to both the Alpine Immune Sciences, Inc. and Vertex Pharmaceuticals teams! *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

We are pleased to announce one of our private investments, ProfoundBio entered into an agreement to be acquired by Genmab (NASDAQ: GMAB) for $1.8B USD in an all-cash deal.?The acquisition is expected to close in the first half of 2024.?Octagon invested in ProfoundBio’s Series B financing earlier this year and is thrilled about the outcome.? ? As stated by Genmab’s President and CEO, Jan van de Winkel, Ph.D., “We believe that ProfoundBio’s ADC candidates, proprietary technology platforms and talented team will be a great addition to Genmab and that, together, we will be able to accelerate the development of innovative, differentiated antibody therapies for cancer patients.”?Additional details can be found in the press release below:? ? https://lnkd.in/eby29f-6 We are super excited for the entire ProfoundBio team and are eager to see Genmab’s advancement of ADCs and ADC technologies for the treatment of cancer.??Congratulations to both teams! *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

We are pleased to announce one of our private investments, AnHeart Therapeutics entered into an agreement to be acquired by Nuvation Bio (NYSE: NUVB) in an all-stock deal.?The acquisition is expected to close in the second quarter of 2024.?As a current board member and the lead investor in AnHeart’s Series B financing we worked closely with AnHeart’s management team throughout the negotiations and are very pleased about the outcome.? ? As stated by Nuvation Bio’s Founder, President and CEO, David Hung M.D., “AnHeart’s lead asset, taletrectinib, which will become our lead asset as it completes two pivotal studies, is a differentiated, next-generation ROS1 inhibitor with a potentially best-in-class profile that may overcome the significant limitations of existing therapies. We are impressed by what the AnHeart team has done to develop this asset and intend to build on the progress made to date.”?Additional details can be found in the press release below:? ? https://lnkd.in/emxNUxGF ? We are super excited for the entire AnHeart Therapeutics team and are eager to see Nuvation Bio’s advancement of Taletrectinib to treat patients with ROS1 NSCLC. Congratulations to both teams! *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

We are excited to announce the latest private investment in our portfolio, ProfoundBio. ? ProfoundBio is a US-based biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer.?ProfoundBio recently announced that it completed an oversubscribed Series B financing which will primarily be used to accelerate the development of its comprehensive ADC portfolio, including the planned pivotal trial of rinatabart sesutecan (Rina-S) for the treatment of ovarian cancer.?Below is a link to the press release: ? https://lnkd.in/ehRqprNS ? We are delighted to be a thought partner for ProfoundBio’s management team as they continue to develop innovative ADCs with the potential for improved clinical outcomes for patients. Congrats to the ProfoundBio team! *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

We are thrilled to share that CymaBay Therapeutics announced that it has agreed to be acquired by Gilead Sciences for $32.50 per share in cash, or a total of $4.3 billion. Below is a link to the press release: ? https://lnkd.in/gZi7p-4x ? Octagon began investing in CymaBay in December 2022 and grew the position to be one of our largest core holdings.?Congratulations to the entire team at CymaBay Therapeutics! *This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.